Can You Take SS-31 Orally? (Bioavailability Explained)

A 2019 pharmacokinetic study published in Clinical Pharmacokinetics found that oral administration of SS-31 resulted in less than 2% systemic bioavailability. Meaning 98% of the dose was degraded by gastric enzymes and never entered circulation. This isn't a formulation problem you can solve with better encapsulation or timing strategies. It's a structural problem: tetrapeptides like SS-31 contain peptide bonds that stomach acid cleaves within minutes of contact.

We've worked with research teams across multiple peptide compounds in this class. The gap between what delivery method people want (oral, convenient, no needles) and what delivery method actually works (subcutaneous, intravenous, bypassing first-pass metabolism) is the single most misunderstood aspect of peptide pharmacology.

Can you take SS-31 orally and expect therapeutic effects?

No. Oral administration of SS-31 (elamipretide) does not produce therapeutic plasma concentrations because gastric acid and proteolytic enzymes in the stomach and small intestine degrade the tetrapeptide before systemic absorption occurs. Clinical trials use subcutaneous or intravenous routes exclusively. Bioavailability via oral dosing is negligible. Approximately 1–2% reaches circulation intact, which is insufficient for mitochondrial targeting.

The assumption that you can take SS-31 orally comes from confusing peptides with small-molecule drugs. Small molecules like metformin or aspirin survive gastric acid and cross the intestinal barrier intact. Peptides. Chains of amino acids linked by peptide bonds. Are structurally vulnerable to the same enzymes your stomach uses to digest dietary protein. SS-31 is a four-amino-acid sequence (D-Arg-Dmt-Lys-Phe-NH2). When exposed to pepsin and trypsin, those bonds break, rendering the compound inactive before it reaches mitochondrial membranes where it would normally function. This article covers why oral delivery fails at the molecular level, what administration routes clinical research actually uses, and what happens when researchers attempt oral formulations with protective coatings or liposomal encapsulation.

Why Oral SS-31 Fails: Peptide Bond Instability in Gastric Acid

SS-31 contains peptide bonds linking four amino acids in sequence. Your stomach produces hydrochloric acid at pH 1.5–3.5 and secretes pepsin. A proteolytic enzyme evolved specifically to cleave peptide bonds in dietary protein. When you take SS-31 orally, pepsin attacks the Arg-Dmt and Lys-Phe linkages within 5–15 minutes of gastric contact. What remains after this enzymatic degradation are free amino acids and dipeptide fragments. None of which retain the parent compound's ability to target cardiolipin in the inner mitochondrial membrane.

Even if a peptide survives gastric acid (which SS-31 does not), it must then cross the intestinal epithelium. A lipid bilayer designed to exclude hydrophilic molecules larger than 500 Da. SS-31 has a molecular weight of approximately 640 Da and carries multiple positive charges at physiological pH, making passive diffusion across enterocytes negligible. Active transport mechanisms for peptides (PEPT1, PEPT2) preferentially shuttle di- and tripeptides, not intact tetrapeptides with modified residues like Dmt (dimethyltyrosine).

Clinical pharmacokinetic studies confirm this. A Phase 2 trial evaluating elamipretide in primary mitochondrial myopathy used subcutaneous injection at 40 mg daily. Oral administration was never considered because preclinical ADME (absorption, distribution, metabolism, excretion) studies demonstrated that oral bioavailability rounded to zero. The compound's half-life in plasma after IV dosing is approximately 1–2 hours, but that presumes the peptide reaches circulation intact. Oral dosing never achieves that baseline condition.

SS-31 Administration Routes Used in Clinical Research

Every published clinical trial evaluating SS-31 for mitochondrial dysfunction, heart failure, or Barth syndrome has used either subcutaneous injection or intravenous infusion. The TAZPOWER trial, a Phase 3 study in Barth syndrome patients, administered elamipretide at 40 mg subcutaneously once daily for 12 weeks. Plasma concentrations peaked at approximately 200–400 ng/mL within 30–60 minutes post-injection and declined with a terminal half-life of 90–120 minutes. Sufficient to sustain mitochondrial membrane interaction across multiple dosing cycles.

Intravenous administration achieves higher peak plasma levels but requires clinical supervision and venous access, limiting practical use to hospital or infusion centre settings. Subcutaneous self-administration. The same technique used for insulin or GLP-1 agonists. Became the standard because it balances bioavailability (near 100% of the dose enters systemic circulation) with patient autonomy. Injection site reactions occur in approximately 15–20% of subjects but are typically limited to transient erythema or mild induration at the administration site.

No oral formulation of SS-31 exists in clinical development as of 2026. Attempts to encapsulate peptides in enteric coatings or liposomal carriers improve gastric survival marginally but do not solve the intestinal permeability problem. Even if 10% of an oral dose survived digestion (an optimistic estimate), crossing the gut barrier would reduce that further to 1–2% systemic availability. A level insufficient to saturate cardiolipin binding sites in mitochondria.

What Research Shows About Peptide Oral Delivery Strategies

Researchers have attempted multiple strategies to enable oral peptide delivery across therapeutic classes. None have succeeded for compounds structurally similar to SS-31. Enteric coatings delay release until the small intestine, reducing pepsin exposure but not eliminating trypsin and chymotrypsin activity in the duodenum. Permeation enhancers like sodium caprate or medium-chain fatty acids temporarily disrupt tight junctions between enterocytes, increasing paracellular transport. But this approach works primarily for smaller peptides (GLP-1 analogs like oral semaglutide) and even then achieves only 0.4–1% bioavailability, requiring dose escalation to 14 mg oral to match 1 mg subcutaneous.

SS-31's therapeutic mechanism depends on precise mitochondrial membrane targeting. The compound's aromatic-cationic motif allows it to cross both the outer and inner mitochondrial membranes and selectively bind cardiolipin. A phospholipid unique to the inner membrane where it stabilises the electron transport chain. Fragmented peptides or free amino acids from oral degradation cannot replicate this targeting. You either deliver the intact tetrapeptide to circulation or you deliver nothing pharmacologically active.

One study published in Journal of Controlled Release tested SS-31 encapsulated in PLGA nanoparticles with a mucoadhesive chitosan coating. A formulation designed to protect the peptide during gastric transit and prolong intestinal contact time. Oral bioavailability improved from <2% to approximately 6–8%, but even this required a 10× dose increase relative to subcutaneous administration to achieve equivalent plasma AUC. The cost, formulation complexity, and dose escalation required made the approach clinically impractical.

SS-31 Orally: Comparison of Administration Routes

What If: SS-31 Oral Dosing Scenarios

What If I Take SS-31 Orally Anyway — Will I Get Any Effect?

No therapeutic effect is expected. Gastric enzymes cleave the peptide bonds within minutes, leaving free amino acids that your body processes as dietary protein. Not as a mitochondrial-targeting agent. The 1–2% that might survive digestion and reach circulation is orders of magnitude below the concentration required to saturate cardiolipin binding sites in the inner mitochondrial membrane. Clinical efficacy in trials required plasma levels of 200–400 ng/mL sustained over hours, which oral dosing cannot achieve even at massively escalated doses.

What If I Use Enteric-Coated Capsules to Protect SS-31 from Stomach Acid?

Enteric coatings delay release until the small intestine, reducing pepsin exposure. But trypsin and chymotrypsin in the duodenum still degrade the peptide. Research using enteric formulations achieved 6–8% bioavailability at best, requiring 10× the subcutaneous dose to match plasma AUC. This dose escalation increases cost proportionally and introduces variability in absorption depending on gastric emptying rate and intestinal pH. No commercial enteric SS-31 product exists because the marginal improvement does not justify the formulation complexity or dose burden.

What If Research Develops an Oral SS-31 Formulation in the Future?

It's unlikely to replicate subcutaneous efficacy without breakthrough permeation technology. Oral semaglutide. The most successful oral peptide to date. Achieves only 0.4–1% bioavailability even with the SNAC absorption enhancer and requires 14 mg oral to match 1 mg subcutaneous. SS-31 is a smaller peptide but lacks the structural modifications (e.g., fatty acid chains, PEGylation) that improve GLP-1 stability. Until a fundamentally new delivery platform emerges, subcutaneous injection remains the only practical route for mitochondrial-targeting peptides in this class.

The Blunt Truth About Oral Peptide Delivery

Here's the honest answer: you cannot take SS-31 orally and expect it to work. Not with better timing, not with protective coatings, not with liposomal encapsulation. The problem is not solvable with minor formulation tweaks. It is a fundamental structural incompatibility between peptide chemistry and the gastric environment. Your stomach evolved to digest protein. SS-31 is a protein fragment. The outcome is predetermined.

Research teams have spent decades attempting to enable oral peptide delivery across dozens of therapeutic targets. The few marginal successes (oral semaglutide, oral calcitonin) required novel permeation enhancers, massive dose escalation, and acceptance of <1% bioavailability as a tolerable trade-off. SS-31's therapeutic window and mitochondrial targeting precision do not allow that trade-off. If you want the compound to reach cardiolipin in the inner mitochondrial membrane, you administer it subcutaneously or intravenously. There is no third option that delivers comparable efficacy.

SS-31's mitochondrial mechanism is what makes it therapeutically interesting. And what makes oral delivery chemically impossible. The same aromatic-cationic motif that allows selective cardiolipin binding also makes the peptide vulnerable to proteolytic degradation. You can have the mechanism or you can have oral convenience. You cannot have both. Real Peptides supplies research-grade SS-31 for laboratory use, and every protocol we've reviewed administers it via injection for exactly this reason. The science does not support oral dosing, and no amount of formulation engineering changes the underlying peptide bond chemistry.

For researchers evaluating SS-31 in mitochondrial dysfunction models, route of administration is not a variable you can optimise around cost or convenience. It is a binary constraint: if the peptide does not reach circulation intact, the experiment fails. Subcutaneous protocols using Cerebrolysin or similar peptide-based compounds consistently demonstrate this principle. Therapeutic outcomes scale directly with bioavailability, and bioavailability from oral dosing is functionally zero for compounds in this structural class. If your research design depends on systemic peptide delivery, plan for injection from the beginning. Oral administration is not a fallback option. It is a non-starter.

Oral peptide delivery remains an active area of pharmaceutical research, but as of 2026, no commercial product has solved the problem for tetrapeptides like SS-31. The gap between what patients want (a pill) and what chemistry allows (an injection) has not closed. And structural biology suggests it may never close for this compound class without a fundamentally new absorption mechanism that does not yet exist.